Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Part of paid clinical trials in Tucson, Arizona.

Sponsor
GlaxoSmithKline
Study ID
NCT04484623
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Belantamab mafodotin — DRUG
    Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
  • Pomalidomide — DRUG
    Immunomodulatory drug (IMiD) will be administered.
  • Dexamethasone — DRUG
    Synthetic glucocorticoid with anti-tumor activity will be administered.
  • Bortezomib — DRUG
    Proteasome Inhibitor will be administered.

Study Details

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

Key Dates

Start date
Oct 1, 2020
Status verified
Mar 2025
Primary completion
Jan 29, 2024
Completion
Oct 25, 2029

Study Design

Enrollment
302 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: Belantamab mafodotin plus Pomalidomide and Dexamethasone
  • Active Comparator: Arm B: Bortezomib plus Pomalidomide and Dexamethasone

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: Up to approximately 174 weeks ]

Locations (5)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteTucsonArizona85712-
GSK Investigational SiteFort MyersFlorida33901-
GSK Investigational SiteBostonMassachusetts02215-
GSK Investigational SiteKansas CityMissouri64132-
GSK Investigational SiteNashvilleTennessee37203-

Find similar trials in Tucson, AZ

By condition

Related Studies